Barclays
CERE

Barclays’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Barclays’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,865
Closed -$2.08M – 5566
2024
Q2 		$2.08M Sell
50,865
-43,083
-46% -$1.79M ﹤0.01% 2111
2024
Q1 		$3.97M Sell
93,948
-258,414
-73% -$10.9M ﹤0.01% 2019
2023
Q4 		$14.9M Buy
352,362
+206,452
+141% +$5.93M 0.01% 1223
2023
Q3 		$3.19M Buy
145,910
+14,568
+11% +$365K ﹤0.01% 1602
2023
Q2 		$4.18M Sell
131,342
-469,712
-78% -$14.4M ﹤0.01% 1451
2023
Q1 		$14.7M Buy
601,054
+144,439
+32% +$4.24M 0.01% 986
2022
Q4 		$14.4M Buy
456,615
+358,880
+367% +$10.1M 0.01% 1035
2022
Q3 		$2.76M Buy
97,735
+94,920
+3,372% +$2.83M ﹤0.01% 1524
2022
Q2 		$74K Sell
2,815
-4,002
-59% -$114K ﹤0.01% 3897
2022
Q1 		$239K Buy
+6,817
New +$199K ﹤0.01% 3315

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Barclays's CERE Position: Q3 2024 in Review

Barclays sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 50,865 shares — an estimated $2.08M sold.

Barclays first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $14.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Barclays reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Barclays sold 50,865 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.08M.
  • Barclays first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • Barclays's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $14.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.